JP2017510641A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510641A5
JP2017510641A5 JP2017502932A JP2017502932A JP2017510641A5 JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5 JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5
Authority
JP
Japan
Prior art keywords
cancer
nitrogen
independently selected
oxygen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502932A
Other languages
English (en)
Japanese (ja)
Other versions
JP6757312B2 (ja
JP2017510641A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022841 external-priority patent/WO2015148854A1/en
Publication of JP2017510641A publication Critical patent/JP2017510641A/ja
Publication of JP2017510641A5 publication Critical patent/JP2017510641A5/ja
Application granted granted Critical
Publication of JP6757312B2 publication Critical patent/JP6757312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502932A 2014-03-27 2015-03-26 置換インドールmcl−1阻害剤 Active JP6757312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971023P 2014-03-27 2014-03-27
US61/971,023 2014-03-27
PCT/US2015/022841 WO2015148854A1 (en) 2014-03-27 2015-03-26 Substituted indole mcl-1 inhibitors

Publications (3)

Publication Number Publication Date
JP2017510641A JP2017510641A (ja) 2017-04-13
JP2017510641A5 true JP2017510641A5 (cg-RX-API-DMAC7.html) 2018-05-17
JP6757312B2 JP6757312B2 (ja) 2020-09-16

Family

ID=54196421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502932A Active JP6757312B2 (ja) 2014-03-27 2015-03-26 置換インドールmcl−1阻害剤

Country Status (7)

Country Link
US (3) US10533010B2 (cg-RX-API-DMAC7.html)
EP (1) EP3122353B1 (cg-RX-API-DMAC7.html)
JP (1) JP6757312B2 (cg-RX-API-DMAC7.html)
CN (1) CN106456602B (cg-RX-API-DMAC7.html)
AU (1) AU2015235944B2 (cg-RX-API-DMAC7.html)
CA (1) CA2943815C (cg-RX-API-DMAC7.html)
WO (1) WO2015148854A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015235944B2 (en) 2014-03-27 2020-06-25 Vanderbilt University Substituted indole Mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
WO2017147410A1 (en) * 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
CA3016182C (en) * 2016-03-04 2024-02-27 Vanderbilt Universtiy Substituted indole mcl-1 inhibitors
PT3445767T (pt) 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
JP7013389B2 (ja) * 2016-05-19 2022-01-31 バイエル アクチェンゲゼルシャフト 大環状インドール誘導体
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
EP3618831A4 (en) * 2017-04-30 2021-12-01 Development Center for Biotechnology ANTI-CANCER FOOT MEDICINE
WO2019040511A1 (en) * 2017-08-22 2019-02-28 University Of Maryland Batimore DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS
EP3710448A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
US11401278B2 (en) 2017-11-17 2022-08-02 The Broad Institute, Inc. Macrocyclic indole derivatives
UY37971A (es) 2017-11-17 2019-06-28 Bayer Ag Derivados de indol macrocíclicos sustituidos
US20210253598A1 (en) 2017-11-17 2021-08-19 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
US11447504B2 (en) 2017-11-17 2022-09-20 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096909A1 (en) 2017-11-17 2019-05-23 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
CN109988151B (zh) * 2017-12-29 2021-04-23 北京赛特明强医药科技有限公司 一种炔类化合物、制备方法及其应用
AU2019223182B2 (en) 2018-02-26 2021-08-19 Gilead Sciences, Inc. Substituted pyrrolizine compounds as HBV replication inhibitors
CN108251104B (zh) * 2018-02-27 2019-11-05 山东大学 一种取代吲哚-2-羧酸类Bcl-2小分子荧光探针及其应用
KR20240165483A (ko) * 2018-05-14 2024-11-22 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
JP2021529785A (ja) * 2018-06-25 2021-11-04 スウヂョウ メドネス ファーマ テック カンパニー リミテッド ヘッジホッグ経路に関連する状態の治療のための化合物および方法
EP3856258B1 (en) * 2018-09-27 2024-07-31 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
TWI749404B (zh) 2018-11-22 2021-12-11 大陸商蘇州亞盛藥業有限公司 作為mcl-1抑制劑的大環吲哚
WO2020147802A1 (en) 2019-01-18 2020-07-23 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic spiroethers as mcl-1 inhibitors
CN114127079A (zh) 2019-05-17 2022-03-01 布罗德研究所有限公司 制备大环吲哚的方法
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
AU2023389065A1 (en) * 2022-12-06 2025-06-19 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703053A (en) 1985-10-28 1987-10-27 Warner-Lambert Company Benzothiophenes and benzofurans and antiallergic use thereof
GB8531612D0 (en) 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
DE4128015A1 (de) 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5436264A (en) 1993-08-19 1995-07-25 Syntex (U.S.A.) Inc. N-aryloxyalkyl tryptamine α1 -adrenergic receptor antagonists
JP3739432B2 (ja) 1994-02-25 2006-01-25 ダイセル化学工業株式会社 オゾン開裂反応
WO1997042188A1 (en) 1996-05-08 1997-11-13 Kumiai Chemical Industry Co., Ltd. Indolyl-substituted uracil derivatives and herbicides comprising them as active ingredients
AU738048B2 (en) 1996-09-12 2001-09-06 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
FR2761070B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761073B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU2002211901A1 (en) 2000-10-10 2002-04-22 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR-gamma binding agents
FR2827287B1 (fr) 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1886133B (zh) 2003-12-04 2010-12-01 财团法人卫生研究院 吲哚化合物
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
US8097644B2 (en) 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
KR20090096690A (ko) 2006-12-14 2009-09-14 아스텔라스세이야쿠 가부시키가이샤 Crth2 길항제 및 항알레르기제로 유용한 폴리사이클릭 산 화합물
MX2009011211A (es) * 2007-04-16 2009-10-30 Abbott Lab Indoles sustituidos en la posicion 7 inhibidores de mci-1.
EP2134685B1 (en) * 2007-04-16 2015-09-02 AbbVie Inc. 7-nonsubstituted indole derivatives as mcl-1 inhibitors
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
JP5731986B2 (ja) 2008-12-09 2015-06-10 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Mcl−1の特異的調節の方法及び組成物
FR2961393B1 (fr) 2010-06-16 2013-02-15 Oreal Procede de coloration capillaire a partir d'une composition comprenant au moins un compose indolique ou une indolinique, un sel metallique, du peroxyde d'hydrogene et un agent alcalinisant
CA2810499A1 (en) * 2010-09-08 2012-03-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatio N P53-mdm2 antagonists
JP2014509850A (ja) 2011-03-06 2014-04-24 メルク セロノ ソシエテ アノニム 低フコース細胞株およびその使用
JP6272773B2 (ja) 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドNanjing Allgen Pharma Co. Ltd. Hdac6阻害剤・抗腫瘍剤用複素環アミド化合物
WO2013112878A1 (en) 2012-01-26 2013-08-01 The Penn State Research Foundation Mcl-1 modulating compositions
WO2014047427A2 (en) * 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
US10005728B2 (en) * 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
AU2015235944B2 (en) 2014-03-27 2020-06-25 Vanderbilt University Substituted indole Mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
CA3016182C (en) 2016-03-04 2024-02-27 Vanderbilt Universtiy Substituted indole mcl-1 inhibitors

Similar Documents

Publication Publication Date Title
JP2017510641A5 (cg-RX-API-DMAC7.html)
CN103200822B (zh) 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
CN110776507B (zh) Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
CN110772639B (zh) Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途
JP7028809B2 (ja) コルテキソロン17α-バレレートを含む腫瘍治療に用いるための組成物
CN105163584A (zh) 用于治疗癌症的化合物
JP2019516759A5 (cg-RX-API-DMAC7.html)
JP2013529200A5 (cg-RX-API-DMAC7.html)
JP2013526540A5 (cg-RX-API-DMAC7.html)
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2013529199A5 (cg-RX-API-DMAC7.html)
JP2013526538A5 (cg-RX-API-DMAC7.html)
US12312334B2 (en) Quinoxaline compounds and uses thereof
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
JP2019529475A5 (cg-RX-API-DMAC7.html)
JP2019527239A5 (cg-RX-API-DMAC7.html)
AU2016301212A1 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
CN104755455B (zh) 可用于治疗癌症的巨大戟醇衍生化合物
CN104470509A (zh) 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途
CN102573833A (zh) 癌细胞凋亡
Banik et al. Novel 6, 12-disubstituted chrysene as potent anticancer agent: synthesis, in vitro and in vivo study
TW202406903A (zh) 聯芳組成物和調控激酶級聯之方法
CN107638426B (zh) 噻唑类化合物在制备治疗肿瘤的药物中的用途
JP2020533399A (ja) 新規低分子化合物
TW201231470A (en) 4-anilinofuro[2,3-b]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same